# WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults

> **NCT07216651** · — · COMPLETED · sponsor: **Closed Loop Medicine** · enrollment: 20 (actual)

## Conditions studied

- Obesity & Overweight

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07216651
- **Lead sponsor:** Closed Loop Medicine
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-09-23
- **Primary completion:** 2026-02-27
- **Final completion:** 2026-03-18
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07216651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07216651, "WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07216651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*